6 results about "Complete adjuvant" patented technology

The application discloses a SjHNF4 polypeptide antibody, a preparation method and application. The preparation method comprises the following steps: downloading a SjHNF4 protein sequence, screening a polypeptide sequence, adding a cysteine at an N terminal, then performing polypeptide synthesis and purification, coupling to obtain a recombinant polypeptide, mixing the coupled polypeptide with Freund's complete adjuvant to obtain a mixture, immunizing a mammal by using the mixture, taking heart blood of the mammal and separating serum to obtain a polypeptide antibody. The polypeptide antibody is detected by using an ELISA method, and then the polypeptide antibody is purified by using a polypeptide affinity chromatographic column. Finally, the binding affinity of the antibody and the antigen is detected by Western Blot and immunofluorescence experiments. The polypeptide antibody obtained by the application has high purity (not less than 90%) and high titer (not less than 512000), and has good purity and immunogenicity, can satisfy various experimental requirements and has commercial value.

The present application relates to the biomedical technology field, disclose a kind of dry syndrome intestinal damage mouse model construction method and its application.The construction method includes: (1) preparation contains Freund's complete adjuvant and 1mg / mL mouse intestinal epithelial cell antigen immunization emulsifier I and preparation contains Freund's incomplete adjuvant and 0.5mg / mL mouse intestinal epithelial cell antigen immunization emulsifier II;(2) to mouse injection the immunization emulsifier I or the immunization emulsifier II in batches, obtain the dry syndrome intestinal damage mouse model.The dry syndrome intestinal damage mouse model construction method provided by the present application only immunizes mouse by mouse intestinal epithelial cell antigen and adjuvant, obtains the mouse model that simultaneously shows dry syndrome and intestinal damage.The construction method not only has the advantages of high efficiency, fast, economic, but also is extremely easy to popularize and widely used, has good application value.

The invention relates to the field of animal disease models, and discloses an improved progressive immune checkpoint inhibitor related myocarditis mouse model as well as a construction method and application thereof. The construction method of the model comprises the steps that 0.1 mL of a Freund's complete adjuvant mixed solution is subcutaneously injected into a mouse on the 0th day and the 7th day, and the solution contains 0.25 mg of a mouse cardiac troponin I immunogenic peptide fragment; the method is characterized in that a PD-1 inhibitor and a CTLA-4 inhibitor are jointly injected into a mouse in a caudal vein mode at the frequency of one time every two days from the eighth day, the injection dosage of each drug is 5 mg / kg per time, and the injection process is carried out for 5 times in total. According to the application, cardiac inflammation caused by ICIs drugs is induced through combined use of various reagents, and a disease outcome stage of a patient in the real world is perfectly simulated through dose control and injection method improvement, so that a bedding effect is achieved for clinical research and drug test.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody for HPV16 type E7 protein detection and application of the monoclonal antibody. E7 protein serving as an antigen and a Freund's complete adjuvant are mixed, then a mouse is subjected to primary immunization, then the E7 protein and a Freund's incomplete adjuvant are mixed, then the mouse is subjected to enhanced immunization, and the HPV16 type E7 protein detection monoclonal antibody is obtained. The monoclonal antibody for detecting the HPV16 type E7 protein is prepared by taking mouse splenocytes and myeloma cells to be fused to prepare hybridoma cells, then performing clone detection on the hybridoma cells to screen the hybridoma cells aiming at the specificity of the HPV16 type E7 protein, and finally obtaining the monoclonal antibody for detecting the HPV16 type E7 protein. According to the present invention, the HPV16 type E7 antigen detection kit is developed by using the immunochromatography method, and the kit has advantages of high sensitivity, strong specificity, simple operation and fast detection speed, and can be used for rapid screening diagnosis and illness state monitoring of HPV16.

The application discloses a specific antibody targeting a lysine K1106 site of an ITSN1-S protein lactylation and a preparation method and application thereof, and the preparation method comprises the following steps: mixing and emulsifying an ITSN1-S-K1106 lactylation antigen with Freund's complete adjuvant and Freund's incomplete adjuvant respectively to obtain a first immunization liquid drop and a booster immunization liquid drop, performing animal immunization by using the first immunization liquid drop and the booster immunization liquid drop respectively, and separating the specific antibody targeting the lysine K1106 site of the ITSN1-S protein lactylation from blood of the immunized animal.The antibody provided by the application can specifically detect the lactylation modification condition of the human ITSN1-S protein from the cell and tissue levels in actual application, and is helpful to explore the action mechanism of post-translational modification of the ITSN1-S protein in tumor proliferation, migration and the like, and provides a potential action target for clinical diagnosis and treatment of tumor diseases.

This invention utilizes an insect-baculovirus expression system to prepare the recombinant protein SADS-CoV-S of porcine acute diarrhea syndrome coronavirus, which is then used to prepare egg yolk antibodies. By optimizing the composition of the subunit vaccine composition for immunizing laying hens, IL-2 and ZnCl2 solution are added as immunostimulants to the conventional adjuvant, increasing the antibody concentration in the egg yolk antibody extract and improving the neutralizing antibody titer and protective efficacy. When IL-2 and zinc chloride aqueous solution are added to the immunization composition simultaneously, the resulting egg yolk antibody aqueous solution exhibits the highest protein concentration, and at the same protein concentration, the egg yolk antibody has the highest neutralizing titer. Compared to the immunization composition using Freund's complete adjuvant alone, the neutralizing titer is increased by more than 60 times.